Weizmann Lab

Since the program opened in 2016, 23 Zuckerman labs have been established in Israel.

Interested in applying for the faculty scholars program?

Eligibility
Weizmann_Yossi
Principal Investigator
Dr. Yossi Weizmann

Zuckerman Faculty Scholar
at Ben-Gurion University of the Negev

Weizmann_Yossi
Weizmann Lab
Synthetic nucleic acid and plasmonic nanomaterials design group
Lab Established 2020 Q&A with Yossi Weizmann

Lab Research Areas

The lab’s research is concerned with the application of nanoparticles and nucleic acids with the aim of exploring and exploiting nanoscale advantages in the world of material chemistry, to address significant chemical, biochemical, and technological problems. By approaching nanoscience from a multidisciplinary perspective, integrating biomaterials, inorganic materials, and small molecules via noncovalent and covalent interactions, the Weizmann group develops new hybrid materials with emergent properties. Their main research objectives are the development of novel strategies and approaches, providing versatile tools to form composite, nano-scaled, precisely-controlled structures and ultra-sensitive DNA machineries.

Scholar Profile

Yossi Weizmann joins the faculty at Ben-Gurion University of the Negev as an Associate Professor in the Department of Chemistry, Ilse Katz Institute for Nanoscale Science and Technology.

Dr. Weizmann did research in biosensors and nanostructure materials in the Chemistry Departments of Hebrew University (PhD), MIT (postdoctoral research), and at the University of Chicago (Assistant Professor).  At Chicago, in addition to research, and serving on multiple committees, he established an enthusiastic group of young researchers, some of whom have since received prestigious academic appointments themselves.

At BGU, Dr. Weizmann’s lab continues his research in the detection of biochemical and medically relevant targets via nucleic acid amplification systems, the synthesis of programmable nanomaterials for self-assemblies and plasmonic bioapplications, and the design and construction of synthetic nucleic acid topologies for biomedical and biomimetic applications.

Dr. Weizmann is listed on seven patents, and is the co-founder of Sensona Inc., whose technology provides express molecular analysis to facilitate the diagnosis and treatment of infectious diseases. The technique on which it is based, the polymerase chain reaction (PCR), has been used for some time, but has involved bulky, time-consuming, and costly equipment. Dr. Weizmann’s newer, more accurate, methods allow the thermocycles associated with PCR to take seconds rather than minutes, and use LED energy to miniaturize, enabling portable systems.

Dr. Weizmann has received prestigious long-term grants from both the National Science Foundation and the Israel Science Foundation.

Font Resize
Contrast